Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.

Tytuł :
Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Autorzy :
Mi D; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, No. 156, Nankai Three Road, Tianjin, China. .
Zhang Y; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, No. 156, Nankai Three Road, Tianjin, China.
Pokaż więcej
Źródło :
Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2020 Mar; Vol. 301 (3), pp. 779-785. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Publication: Berlin : Springer Verlag
Original Publication: München : Springer International, c1987-
MeSH Terms :
Biomarkers, Tumor/*blood
Fallopian Tube Neoplasms/*blood
Ovarian Neoplasms/*blood
Peritoneal Neoplasms/*blood
WAP Four-Disulfide Core Domain Protein 2/*genetics
Adult ; Aged ; Fallopian Tube Neoplasms/mortality ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/pathology ; Prognosis ; Survival Analysis
Contributed Indexing :
Keywords: CA125*; Diagnosis*; Human epididymis protein 4*; Prognosis*; Recurrence*; Treatment response*
Substance Nomenclature :
0 (Biomarkers, Tumor)
0 (WAP Four-Disulfide Core Domain Protein 2)
0 (WFDC2 protein, human)
Entry Date(s) :
Date Created: 20200209 Date Completed: 20200831 Latest Revision: 20200831
Update Code :
20201023
DOI :
10.1007/s00404-020-05447-z
PMID :
32034508
Czasopismo naukowe
Purpose: In this study, the prognostic value of serum HE4 was investigated in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Methods: Serum HE4 and CA125 levels were measured in both patients and controls, and the response of treatment and the detection of recurrence were evaluated by serum HE4 and CA125 levels in the patients.
Results: The results showed that the levels of serum HE4 and CA125 were significantly higher in advanced patients than those seen in benign disease controls (p < 0.001). Compared with CA125, HE4 had higher specificity, but lower sensitivity. Furthermore, serum HE4 was closely associated with the response of treatment and recurrence, the effective response rate for therapy treatment showed by HE4 was higher than CA125, and a serum HE4 level was correlated with a sensitivity of 82.8% and a specificity of 99%, a positive predictive value (PPV) of 97.7%, and a negative predictive value (NPV) of 77.9% to show the presence of recurrence; the accuracy of HE4 for recurrence prediction after treatment was 88.6%.
Conclusions: Our study indicated that serum HE4 levels are effective for diagnosis, evaluating the response of treatment and predicting recurrence in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies